[A19-74] Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V

Last updated 02.12.2019

Project no.:

Commission awarded on 29.08.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Airways and respiratory system


Adolescents and adults with inadequately controlled severe asthma with type 2 inflammation who are already receiving high-dose inhaled corticosteroids and at least 1 other medicinal product for maintenance treatment

Result of dossier assessment:

Added benefit not proven due to lack of suitable study data


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

informedhealth.org logo Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form